Mutz Christopher 4

What Happened
Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals (ANIP), had 4,546 shares withheld on Feb 11, 2026 to satisfy tax withholding related to vested performance stock units. The shares were valued at $76.25 each, totaling approximately $346,633. This was a tax-withholding disposition (transaction code F), not an open-market sale.

Key Details

• Transaction date and price: 2026-02-11 at $76.25 per share (4,546 shares; ~$346,633).
• Transaction type: F (shares withheld for tax purposes) — disposition to cover taxes on vesting.
• Related award: Withholding was in connection with the vesting of 11,578 performance stock units granted Apr 6, 2023 (per footnote). The withholding is reported as exempt under Rule 16(b)-3.
• Shares owned after transaction: Not specified in the filing.
• Filing timeliness: Report filed Feb 13, 2026 for a Feb 11 transaction — appears timely.

Context
Tax-withholding via share surrender is a routine administrative step when equity awards vest; it does not indicate an independent decision to sell shares on the open market and is generally not viewed as a signal of insider sentiment. Rule 16(b)-3 exemption allows companies to withhold shares to satisfy tax obligations without triggering certain liability under short-swing profit rules.